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MicroRNACurrent anti-obesity strategies are aiming at restricting energy uptake, but still, obesity treatment is far from
being satisfactory. The discovery of active brown adipose tissue (BAT) in adult humans currently opens new
avenues to combat obesity and follow-up complications as it tackles the other site of the energy balance: energy
expenditure via non-shivering thermogenesis. This process of energy dissipation in the adipose tissue is tightly
controlled, and the elucidation of its regulatory network is a key plank for therapeutic applications. MicroRNAs
(miRNAs) belong to a novel class of regulatory determinants which are small non-coding RNAs with vital roles
in regulating gene expression that also play a role inmanyhuman diseases. In this reviewwe summarizemiRNAs
which have been shown to govern thermogenic, i.e. brite or brown, adipocyte recruitment and physiology.
Notably, most miRNAs in this context have so far been characterized solely in mice, revealing a great demand
for more human studies. As in the context of other diseases, RNA-based therapeutics have meanwhile entered
clinical trials, further exploring the functions of miRNAs in brown and white adipose tissues could result in
novel therapeutic approaches to treat obesity and its follow-up complications.
© 2014 Karbiener and Scheideler. Published by Elsevier B.V. on behalf of the ResearchNetwork of Computational
and Structural Biotechnology. This is an open access article under the CC BY license
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The whole body energy balance depends on two sides of the same
coin: energy uptake and energy expenditure. As obesity is a
consequence of energy uptake that exceeds energy expenditure, current43 316 873 105334.
rbiener),
y Elsevier B.V. on behalf of the Resea
nses/by/4.0/).anti-obesity strategies are aiming at restricting energy uptake.
Nevertheless, this treatment strategy acting on one side of the coin is
far from being satisfactory so far, unfortunately [1]. Nowadays, there is
emerging evidence that a lifestyle-modiﬁcation program characterized
by a balanced diet and combinedwith an increase in energy expenditure
can reduce obesity and the risk of obesity-related comorbid condi-
tions [2]. Increased energy expenditure can be achieved either by physi-
cal activity, mainly in the muscle [3], or by non-shivering thermogenesis
in the adipose tissue [4], owing to the fact that active (i.e., thermogenic)rch Network of Computational and Structural Biotechnology. This is an open access article
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humans [5–9]. Indeed, human BAT recruitment and activation upon
cold exposure have very recently been demonstrated to increase non-
shivering thermogenesis, to elevate energy expenditure and ﬁnally to
contribute to body fat reduction [10–12]. These ﬁndings underline the
paradigm shift that recruitment and activation of thermogenic
adipocytes, i.e. increasing energy combustion in the adipose organ by
non-shivering thermogenesis,might contribute to anti-obesity strategies
[13].
Thermogenic adipocytes are distinct from white adipocytes in that
they have more mitochondria, and in that uncoupling protein 1
(UCP1) is highly enriched in these mitochondria. UCP1 uncouples sub-
strate oxidation from ATP production so that heat is generated instead
[14]. In addition to thermogenic brown adipocytes which are located
in BAT, upon cold exposure, UCP1-expressing thermogenic adipocytes
can also be recruited in white adipose tissue (WAT), so-called brite
(brown-in-white) or beige adipocytes, resulting in WAT ‘browning’
[15–19]. Thermogenic adipocytes have a substantial impact on the
energy balance, as UCP1-promoted heat production – non-shivering
thermogenesis – is a highly energy-dissipating process [20,21].
This attracts constantly growing attention in the search for molecu-
lar pathways, pharmacological agents and endogenous signals that reg-
ulate the formation of thermogenic adipocytes [22–24]. As proof of
concept, ﬁrst promising targets in human have already been identiﬁed
comprising endocrine and paracrine mediators such as FGF21 [25,26]
and natriuretic peptides [27–29], as well as transcriptional regulators
such as PPARγ2, C/EBP and PRDM16 [30].
However, the role of non-coding RNAs (ncRNAs), a novel class of
regulatory determinants, is still mostly unknown in this context. The
best explored subclass of ncRNAs comprises microRNAs (miRNAs),
small RNAs of approximately 23 nucleotides, which play a central role
in RNA interference (RNAi), a post-transcriptional gene silencingmech-
anism existing in many eukaryotes [31–34]. MiRNAs interact with par-
tially complementary sites in the 3′UTR of mRNAs to diminish protein
output, via both inhibition of translation and mRNA destabilization
[35]. Despite their recent discovery, it is already well-known that
miRNAs play pivotal roles in numerous biological processes. Important-
ly, fat-selective inactivation of Dicer, a necessary factor for miRNA
biogenesis, has been shown to result in mice that were almost devoid
of WAT [36], which implicates miRNAs in adipocyte development.
Indeed, we [37–39] and others [40,41] have identiﬁed miRNAs that in-
ﬂuence white adipocyte differentiation. In this review we summarize
the currently known roles of miRNAs in the recruitment and function
of thermogenic adipocytes.
2. MicroRNAs in brite/brown adipocyte differentiation and function
2.1. MiR-193b-365 involvement in brown adipocyte differentiation
Although white and brown adipocytes share morphological similar-
ities (most importantly, lipid droplets), some recent studies have accu-
mulated evidence for a close developmental relationship between
brown and myogenic lineages, at least in mouse [42–44]. In extension
of these ﬁndings, a study by Lodish and co-workers demonstrated that
miRNAs can act as gatekeepers between brown adipogenesis and
myogenesis [45]. First, the authors found miR-193b and miR-365,
which are expressed from the same locus, to be enriched in mouse
BAT versus WAT and other tissues. Second, inhibition of both miRNAs
(by locked nucleic acid modiﬁed antisense oligonucleotides (LNA-
ASOs)) suppressed adipocyte differentiation of precursor cells isolated
from either BAT or WAT. As in brown precursors, this inhibition
elevated themRNAs ofmyogenic factor 6 (Myf6) andmyogenic differen-
tiation 1 (Myod1), a possible involvement of the miRNAs in myogenesis
could be anticipated, and indeed, overexpression of miR-193b and/or
miR-365 in C2C12 myoblasts impaired myogenic differentiation while
promoting adipogenesis. However, the relevance of these in vitro resultshas recently been challenged by the investigation of a mouse model in
which the miR-193b gene as well as upstream regulatory sequences
were deleted, thereby preventing the expression of both miR-193b and
miR-365 [46]. Interestingly, the morphology of BAT and the expression
of brown markers (Ucp1, PR domain containing 16 (Prdm16)) were
not different between miR-193b−/− and control (miR-193b+/+) mice.
Likewise, miR-193−/−mice exhibited normal cold tolerance and energy
expenditure upon β3-adrenergic stimulation. Further, Feuermann et al.
did not observe defects in adipocyte differentiation of precursor cells
isolated frommiR-193−/−BAT,which is in direct contrast to the previous
study by Sun et al. Future studies would therefore be in demand to
further investigate the knockout mousemodel, or cells obtained thereof.
2.2. MiR-196a is a positive regulator of brite adipocyte differentiation
MiR-196a was recently introduced as the ﬁrst miRNA to regulate
brite adipogenesis in vitro and in vivo [47]. Indicating a function in the
“browning process”, miR-196a was found to be induced by cold and
β3-adrenergic stimulation in mouse inguinal WAT (iWAT, i.e. posterior
subcutaneous WAT). Furthermore, inhibition of miR-196a during adi-
pocyte differentiation of precursor cells isolated from iWAT largely
prevented the induction of thermogenic markers. Mechanistically, the
effect of miR-196a was delineated to its direct target homeobox C8
(Hoxc8), a transcription factor that is highly enriched in WAT versus
BAT and that represses CCAAT/enhancer binding protein β (C/EBPβ),
an important regulator of brown adipogenesis. Indeed, HOXC8 overex-
pression during adipogenesis of human WAT-derived precursors
suppressed brown marker gene expression, yet only if the miR-196a
binding site within the HOXC8 3′UTR was deleted. The importance of
miR-196a for adipose tissue metabolism was further corroborated by a
transgenic mouse model overexpressing the miRNA under the control
of the aP2 promoter. These mice exhibited a substantial induction of
Ucp1 and other brownmarkers in iWAT, displayed increased energy ex-
penditure and hence were resistant to diet-induced obesity as well as
more sensitive to insulin. In sum, miR-196a and Hoxc8 were identiﬁed
as a novel regulatory axis in adipocyte development. However, it should
be pointed out that miR-196a is also associated with an oncogenic phe-
notype in various malignancies, e.g. colorectal cancer [48], non-small
cell lung cancer [49], glioblastoma [50], and cervical cancer [51],
which might limit its potential therapeutic value.
2.3. MiR-133 is a negative regulator of brite and brown adipocyte
differentiation
The miR-133 family has an established role in the physiology of
cardiac and skeletal muscle [52–54]. In addition, Trajkovski et al. have
described an involvement of miR-133a and -133b in brown and brite
adipogenesis [55]. Cold exposure led to a pronounced decrease of both
miRNAs in mouse BAT and subcutaneous WAT (scWAT). Inhibition of
miR-133a/b during differentiation of immortalized brown preadipocytes
strongly increased the expression of Ucp1 and its upstream regulators
Prdm16 and peroxisome proliferator activated receptor α (Pparα),
resulting in increased cellular respiration. Of note, these browning effects
were accompanied by a general promotion of adipogenesis (assessed by
expression of the adipogenic master regulator peroxisome proliferator
activated receptor γ (Pparγ), and the portion of lipid-ﬁlled cells).
Conversely, transfection of miR-133 mimics blunted the expression of
brown and general adipocyte markers. Similar effects of the miR-133
family were also observed with preadipocytes isolated from scWAT.
Further in vitro experiments demonstrated a novel regulatory cascade
in which β-adrenergic stimulation leads to suppression of the myocyte
enhancer factor 2 (Mef2) transcription factor family, thereby reducing
miR-133a/b levels, leading to increases of the direct miR-133 target
Prdm16 and subsequent browning. A more recent study recapitulated
the negative effect of miR-133a on brown and brite adipocyte differenti-
ation [56]. The authors used a knockoutmousemodel inwhich 3 of the 4
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strong reduction of miR-133a did not affect brown marker gene expres-
sion in BAT, pronounced “browning” of iWATwas observed. Further, glu-
cose tolerance and insulin sensitivity were markedly improved
compared to wild type mice of matched age, gender and genetic back-
ground. Interestingly, the miR-133a/b effects on brown/brite adipocyte
development have recently been demonstrated to extend to the
myogenic lineage. Inhibition of the miR-133 family in satellite cells
(i.e., adult skeletal muscle stem cells) promoted the development of
Ucp1+ and Prdm16+ adipocytes in vitro and in vivo [57]. Collectively,
the studies by Liu et al. and Yin et al. suggest a dual action of miR-
133a/b, governing non-shivering thermogenesis in genuine adipose
tissues as well as in skeletal muscle.
2.4. MiR-155 hampers differentiation of brite and brown adipocytes
MiR-155 was identiﬁed by Chen et al. as another negative regulator
of BAT development and thermogenesis [58]. Using murine brown
preadipocytes, the authors found that miR-155 prevents adipocyte
differentiation via direct targeting of C/ebpβ. In turn, C/ebpβwas dem-
onstrated to suppress transcription of miR-155, thereby establishing a
double-negative feedback loop in brown precursor cells. Strikingly,
transgenic mice that overexpressed miR-155 (globally or speciﬁcally
in BAT) exhibited smaller BAT depots, aswell as reducedUcp1 in the tis-
sue, which was corroborated by decreased BAT-derived thermogenesis.
The in vivo relevance of this miRNA was further supported by a mouse
knockout model: miR-155−/−mice were more resistant to cold stress
thanwild type littermates, presumably due tomoremetabolically active
BAT and browning of iWAT. However, possible consequences of miR-
155 overexpression/deletion on diet-induced weight gain have not
been investigated so far. Further, it should be noted that miR-155 has
profound functions in the hematopoietic system [59]. For instance, in-
validation of the miR-155 gene in mice evoked severe defects in T-cell
differentiation and B-cell differentiation [60]; thus, possible beneﬁcial
metabolic effects of miR-155 antagonism might be paralleled by
detrimental effects on immune responses.
2.5. MiR-27 represses differentiation of brite and brown adipocytes
ThemiR-27 familywas one of theﬁrst thatwas functionally linked to
white adipogenesis [37,61,62], exhibiting a strong anti-adipogenic func-
tion due to direct targeting of the Pparγ 3′UTR [37]. A possible role in
differentiation of brown precursor cells could thus be anticipated and
was recently conﬁrmed, as inhibition of miR-27a/b led to marked in-
creases of Prdm16, Pparα, and peroxisome proliferator activated recep-
tor, γ coactivator 1 α (Pgc1α) mRNAs, Ucp1 protein, as well as
respiratory capacity [63]. Similar positive effects on brown markers
were observed when miR-27a/b were inhibited during differentiation
of stromal vascular cells from scWAT and visceral WAT. Conversely,
these marker genes were repressed if miR-27a levels were elevated
during differentiation via transfection of miRNA mimics. Of interest,
four important transcriptional regulators of the brown gene expression
program – Prdm16, Pparα, cAMP responsive element binding protein 1
(Creb1), and Pgc1β – were validated as direct targets of the miR-27
family, which revealed a direct molecular link of these miRNAs to the
core protein network governing the development of thermogenic
adipocytes.
2.6. MiR-106b-93 is a negative regulator of brown adipocyte differentiation
MiR-106b and miR-93 originate from a single (i.e., polycistronic)
transcript and belong to the miR-17 family which comprises several
othermembers that are partitioned between three distinct miRNA clus-
ters. While the members of one of these clusters – miR-17~92 – were
found to promote (white) adipocyte differentiation of 3T3-L1
preadipocytes [64], Wu et al. recently described a negative effect ofmiR-106b and miR-93 on brown adipogenesis, as inhibition of either
miRNA during differentiation of brown preadipocytes increased lipid
accumulation and the levels of brown and general adipocyte markers
[65]. These diverging resultsmight be explained by the fact that the pre-
vious study overexpressed the entire miR-17~92 cluster which also
comprisesmiRNAsnot belonging to themiR-17 family (i.e. with another
seed sequence). Alternatively, the different developmental origins of
brown as opposed towhite precursor cells might result in different rep-
ertoires of mRNAs that are targeted by members of the miR-17 family.
2.7.MiR-26 family induces andpromotes humanbrite adipocyte differentiation
It should be noted that functional characterization of the above
described miRNAs in brown and brite adipogenesis has been
performed almost entirely in mouse. In contrast, a recent study has
revealed the ﬁrst “browning” effect of miRNAs in human adipogenesis
[39]. MiR-26a and miR-26b levels were found to increase during adipo-
cyte differentiation of human multipotent adipose-derived stem
(hMADS) cells [66,67,18], and their inhibition strongly prevented lipid
accumulation and expression of general adipocyte markers. In contrast,
elevation of miR-26a/b by transfection of mimics modestly accelerated
adipogenesis. Interestingly, global gene expression analysis ofmiR-26a-
transfected cells revealed a signiﬁcant induction of pathways related to
energy dissipation. Brown marker genes – most importantly UCP1 –
were indeed found to be strongly upregulated, leading to increased
basal and uncoupled respiration upon treatment with miR-26.
Mitochondrial morphology was likewise shifted towards a more
brown phenotype. Mechanistically, the combination of transcriptomics,
an RNAi screen, and reporter assays revealed that the effects of miR-
26a/b are largely mediated via its direct target ADAMmetallopeptidase
17 (ADAM17/TACE), a gene thatwas previously described to negatively
regulate non-shivering thermogenesis [68,69]. Finally, miR-26a was
found enriched in mouse BAT versus WAT, and to be induced in WAT
upon cold exposure, which further supports a physiological relevance
of the miR-26 family that could also be utilized for therapeutic
purposes.
3. Summary and outlook
As overweight and obesity have reached pandemic dimensions, the
demand for treatments which effectively promote weight loss is higher
than ever. In this respect, approaches aimed to reduce energy intake
(either intestinal absorption of nutrients, or central regulation of
appetite) have been pursued for decades, yet have continuously failed
to reduce body fat on a long-term perspective. Recently, the alternative
concept of promoting energy expenditure via activation and recruit-
ment of thermogenic adipocytes has been revitalized as several studies
have demonstrated the presence of BAT in healthy adults. Indeed, the
ﬁnding that BAT activity is inversely correlated with BMI in humans
[7] suggests a physiological relevance for brown and brite adipocytes
in the control of body weight, as has been demonstrated for mice [20].
The development of pharmacological compounds able to promote
glucose and fatty acid oxidation, either by activation of pre-existing
thermogenic adipocytes or their de novo recruitment, is therefore
heavily pursued by both academia and the biotech industry, not least
due to interesting therapeutic perspectives.
It is however evident that the molecular mechanisms governing
white, brown and brite adipocyte development are still incompletely
elucidated. This is especially true for human, as the vast majority of
studies in adipocyte biology has been performed in mouse or cells de-
rived thereof. Further, the more recently discovered classes of ncRNAs
remain largely uncharacterized with respect to their impact on metab-
olism. MiRNAs are one such class, with only a few studies published to
date that describe an impact on thermogenic adipocyte development.
Due to the nature of miRNAs to simultaneously act on a large set of
mRNA targets, they appear as powerful determinants in cell fate
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Likewise, a strong involvement of particularmiRNA families in complex
diseases like obesity and diabetes can be anticipated. As for other dis-
eases, it should be noted that therapeutic approaches aimed to antago-
nize or restore miRNA function have already made their way “from
bench to bedside”: While an anti-miR-122 inhibitor compound has
been shown to effectively reduce hepatitis C viral load in a phase 2a clin-
ical trial [73], a miR-34 mimic with the perspective to treat liver cancer
has recently entered phase 1 [74]. It is thus conceivable that future re-
search further exploring the molecular actions of miRNAs in adipocytes
and adipose tissue will reveal pharmacological ways to promote energy
expenditure in fat cells that could eventually result in novel anti-
obesity therapeutics.
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